Competitive Advantages
The advantage that held up for Selah Genomics was institutional placement: its Clinical Genomics Center operated inside the Greenville Health System's Institute for Translational Oncology Research, and a second center at the University of South Carolina in Columbia, South Carolina, so a rival copying it had to replicate that institutional footing rather than merely a test menu.
Selah Genomics also entered a partnership with Foundation Medicine and the Greenville Health System to launch a Rare Tumor Center, giving patients molecular profiling of rare cancer tumors through the FoundationOne test.
Risk Factors
Selah Genomics faced a financing risk tied to its loss-making record: it posted a loss after tax of £0.6 million for the period from acquisition to 31 December 2014 and an unaudited loss after tax of £2.6 million from 1 January 2015 to 30 November 2015, and it appeared on the Company's balance sheet as of 31 December 2014 within intangible assets valued at £41.4 million to be written off, observable warnings that its ongoing funding relied on an owner prepared to continue absorbing those losses.
The consideration paid by the Purchasers for Selah Genomics in the acquisition was nominal.
Product Overview
Selah Genomics sold advanced molecular and genomic diagnostic services to healthcare providers and pharmaceutical customers, and its portfolio of advanced diagnostic tests was focused initially on oncology and infectious disease.
Selah operated as a clinical diagnostic company that enabled personalised medicine by detecting molecular biomarkers to diagnose and monitor disease, detect the risk, and identify therapies best suited to individual patients. It maintained a Clinical Genomics Center at the Institute for Translational Oncology Research of the Greenville Health System and a second Clinical Genomics Center at the University of South Carolina in Columbia, South Carolina.
